ADAM17 and Alzheimer disease: The rather ubiquitous expression of both ADAM10 and PrP in different organs, cell types and experimental models, and the current view that no other proteases (such as ADAM17) seem to be involved in PrP shedding, may suggest a potential of measuring sPrP as a surrogate marker for efficacy read-out in any experimental or therapeutic strategies targeting ADAM10, be it stimulation of its protective APP α-secretase activity in the context of AD or inhibition of its rather detrimental effects, e.g. in cancer and inflammatory diseases [107].